SCHEMBL7186760

SCHEMBL7186760

COc1c(Cl)ccc(Cl)c1C(=O)P(=O)(C(=O)c1c(C)cccc1Cl)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TAS1R3 Q7RTX0 8/20 0.43
TAS1R1 Q7RTX1 8/20 0.43
TAS1R2 Q8TE23 6/20 0.43
TSHR P16473 1/20 0.42
NOTUM Q6P988 1/20 0.39
TYK2 P29597 1/20 0.38
ABL1 P00519 1/20 0.38
SRC P12931 1/20 0.38
TRPM4 Q8TD43 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36
ITGB1 P05556 2/20 0.35
ITGA4 P13612 2/20 0.35
ITGA2 P17301 1/20 0.35
ITGB7 P26010 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183280 0.96 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7189534 0.93 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7187679 0.92 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7189336 0.91 TAS1R3 (0.43) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7175812 0.89 TAS1R3 (0.41) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7178072 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7181188 0.88 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7175298 0.87 TOP1 (0.40) ALDH1A1KDM4EHSD17B10TAS1R3TAS1R1
SCHEMBL7182453 0.87 TYK2 (0.44) ALDH1A1TYK2ABL1SRCTRPM4
SCHEMBL7179862 0.87 TYK2 (0.44) ALDH1A1TYK2ABL1SRCTRPM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885KDM4E 3226/4885HSD17B10 56/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885KDM4E 2651/4885HSD17B10 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.